# Ep102: David Baltimore Reflects on a Life in Science

- **Show:** The Long Run with Luke Timmerman
- **Published:** 8 Nov 2021
- **Source:** https://soundcloud.com/longrunpodcast/ep102-david-baltimore-reflects-on-a-life-in-science
- **Transcript:** https://podcasts.opennash.com/shows/the-long-run/ep102-david-baltimore-reflects-on-a-life-in-science-0bc53e/
- **Provider:** OpenNash Podcasts (machine-generated)

## In brief

David Baltimore argues that scientific breakthroughs come from young people given freedom and a broad education, not from narrow, long apprenticeships. He credits a high school summer at Jackson Laboratory, a liberal arts degree at Swarthmore and the Whitehead Fellows program for his own path. He argues science has drifted the wrong way: young researchers now reach independence in their 40s.

The episode follows an hourglass: wide education, a narrow stretch of graduate specialization, then a widening into new fields. Baltimore moved from viruses to cancer, immunology, biotech companies and public debates over recombinant DNA. The tension is between collaboration, which modern tools demand, and the individual imagination he says still drives discovery. He sees institutions giving too little room to the latter.

## Key insights

1. **A high school lab summer set his career** At the Jackson Laboratory in 1955, Baltimore asked questions with no known answer, guided by three mentors who he later learned were leading developmental biologists. He says he discovered that the frontier of knowledge was open to a teenager, and he still wants high schoolers exposed to experiments.
2. **A liberal arts degree prepared him to lead** Baltimore credits Swarthmore with giving him the ability to become a university president. He says high-level administration is about judging people and personal interaction, not technical problems.
3. **Biotech began with a primer supplier** Baltimore needed oligo-dT primers for reverse transcriptase. Ori Friedman's Collaborative Research, formed in the late 1960s, made them, and Baltimore calls it the first biotechnology company. He helped found its offshoot, Collaborative Genetics, in 1975.
4. **Asilomar was in scientists' own interest** Baltimore says scientists needed to address recombinant DNA dangers themselves, partly to avoid public fear shutting down research. For gene editing, he says ethicists now play a much larger role because scientists are no better at the ethical questions.
5. **Delayed independence is hurting young scientists** Long graduate and postdoc training means researchers reach independence around their 40s, when family and other duties pull them away from research. Baltimore says science has gone in exactly the wrong direction, and the Whitehead Fellows program was meant to show another way.

## Questions this episode answers

### What did David Baltimore actually discover?

In the intro, host Luke Timmerman says Baltimore discovered reverse transcriptase, an enzyme that copies viral RNA into DNA. It showed genetic information can flow from RNA back to DNA, which revised the central dogma, and it won him the 1975 Nobel Prize at age 37.

### Why did a company that sold chemicals matter to the start of biotech?

Baltimore needed a short DNA piece called a primer, because his enzyme could not start copying without one. Ori Friedman's Collaborative Research manufactured it, and Baltimore calls it literally the first company in biotechnology.

### Why did scientists hold the Asilomar meeting on recombinant DNA?

Baltimore says scientists wanted to think through the dangers and opportunities of the new gene-splicing methods before others did it for them. He also says public fear could have shut down funding, so it was in scientists' own interests.

### Why does Baltimore think the current research career path is a problem?

He says training now takes so long that researchers often reach independence only in their 40s, when families and other duties pull them away from research. He believes younger, less encumbered scientists find the new directions science needs.

### What would Baltimore study if he were starting today?

He says neuroscience, because how the brain works and processes information is still very obscure. He also names gene regulation, where lipid droplets organizing regulatory machinery are a new puzzle.

## Facts

- **Luke Timmerman** [0:01:50]: "He won the Nobel Prize in 1975 for that work at the age of 37."
- **Luke Timmerman** [0:02:24]: "as the founding director of the Whitehead Institute for Biomedical Research, had a brief stint as president of Rockefeller University, and then served as president of Caltech"
- **Luke Timmerman** [0:02:24]: "and 20 have been elected to the National Academy of Sciences."
- **David Baltimore** [0:14:11]: "That was in 1953. And this was the summer of 1955."
- **David Baltimore** [0:17:59]: "the Swarthmore educational system for honors students was that we took seminars, two seminars a semester for the last two years."
- **David Baltimore** [0:23:56]: "I did an undergraduate thesis in chemistry, but I did it at the University of Pennsylvania"
- **David Baltimore** [0:25:04]: "Cy Leventhal who was one of the early molecular biologists himself actually trained in physics"
- **David Baltimore** [0:27:19]: "Luria had written the then only textbook on virology and had written about animal viruses."
- **David Baltimore** [0:27:19]: "he arranged for me to work the following summer with a quantitative animal virologist, Phil Marcus, and to take a course in Cold Spring Harbor in animal virology"
- **David Baltimore** [0:28:52]: "I switched from MIT, where I had been a graduate student, to Rockefeller and did my thesis with him."
- **David Baltimore** [0:43:44]: "what we discovered very early on was that the reverse transcriptase needed a primer. And that that primer was a piece of DNA that could hybridize to a template at some place, wherever."
- **David Baltimore** [0:44:37]: "messenger RNAs started at their three prime end with a poly A and that was known and so you could copy any messenger RNA using oligo DT as a primer"
- **David Baltimore** [0:44:37]: "there was a company that had been formed in the late 1960s by a chemist at at brandeis university"
- **David Baltimore** [0:45:51]: "It was literally the first company in biotechnology. And what it was formed to do was to manufacture nucleic acids, strings of A's, G's, C's, and T's."
- **David Baltimore** [0:47:36]: "we got together and formed Collaborative Genetics, which was an offshoot of collaborative research. And this is this is 1975."
- **David Baltimore** [0:48:20]: "I brought some friends of mine along with this David Botstein, Jerry Fink, Ron Davis."
- **David Baltimore** [0:38:45]: "Paul Berg, Maxine Singer, and others whom I worked with on this were very important in there"
- **David Baltimore** [0:40:58]: "we had some ethicists we had some lawyers who came we had newspaper people but the core of it was science"
- **David Baltimore** [0:40:58]: "we've now had two summits and are in the process of organizing a third, the ethicists are playing a much larger role"
- **David Baltimore** [0:51:42]: "when I was asked by Jack Whitehead, advise him about forming an institute."
- **David Baltimore** [0:54:35]: "graduate school and postdoctoral training that was increasingly long, five, six years, seven years to train a student, and then another five years for a postdoc"
- **Luke Timmerman** [0:55:35]: "I found that the average first time R01 grant winner when he was coming up was something like 30."
- **David Baltimore** [1:06:34]: "with the recent discoveries of these lipid droplets organizing regulatory machinery, we have a new challenge in front of us"

## Transcript

**[0:00:01] Luke Timmerman:** Welcome to the Long Run. This is a podcast for biotech adventurers. I'm your host, Luke Timmerman. Today's guest is David Baltimore. David is one of the most accomplished biomedical scientists of the past 50 years. He recently won the Lasker-Kochland Award for Special Achievement. The award said that it was granted for, quote, the breadth and beauty of his discoveries in virology, immunology, and cancer, for his academic leadership, for his mentorship of prominent scientists, and for his influence as a public advocate for science.

**[0:00:43] Luke Timmerman:** End quote. That's a lot. It would take way more than an hour to discuss all of his scientific work and his work at the intersections of science and industry and science and society. But for those who could use a very brief history, here goes. David made his name early in his career at MIT with the discovery of enzymes called reverse transcriptases. That work showed the world that the central dogma of biology, popularized by none other than Francis Crick, needed a pretty serious revision.

**[0:01:14] Luke Timmerman:** At the time, the saying was that DNA makes RNA makes protein, and it was thought to be a one-way street of genetic information. Howard Temin at the University of Wisconsin and David Baltimore at MIT both showed that these reverse transcriptase enzymes convert the viral RNA genome of retroviruses into a complementary DNA, a cDNA molecule, which can then integrate into the host genome. In other words, genetic information could flow from RNA back to DNA in certain situations.

**[0:01:50] Luke Timmerman:** and from that point forward, genetic information could be thought of as a two-way street in certain situations. That fundamental work in virology led him down a whole set of interesting paths in immunology and cancer biology. He won the Nobel Prize in 1975 for that work at the age of 37. Now at age 83, Baltimore is in a position to reflect. His career shows amazing range. I've heard one scientist say that Baltimore could easily have won two or even three Nobels.

**[0:02:24] Luke Timmerman:** But there's more to his life than his discoveries. He mentored hundreds of scientists through the years. Many ended up launching independent research careers of their own, and 20 have been elected to the National Academy of Sciences. Leveraging his high-profile platform, Baltimore took on academic leadership posts as the founding director of the Whitehead Institute for Biomedical Research, had a brief stint as president of Rockefeller University, and then served as president of Caltech, where he remains as Professor Emeritus.

**[0:02:55] Luke Timmerman:** Throughout, he sought to be near the action and exert some influence in major bioethical debates of the day. That work dates back to the recombinant DNA controversies of the mid-1970s to the still-simmering CRISPR gene-editing concerns of the present. And like some of the top scientists of his generation, he sought to be something of a bridge between the worlds of science and the society at large. It's always been a tricky balance. He doesn't have all the answers.

**[0:03:25] Luke Timmerman:** He said in this interview that his thinking has evolved on societal debates over time in terms of who should be at the table. It would take at least 20 to 25 hours of interviews for me to fully explore this man's life in science, but I tried in this conversation of one hour to just hit some highlights. We talk about his upbringing, the value of humanity's training for scientists that he got, some early career turning points, how he got involved with biotech as the industry began to emerge, and the kind of opportunities he'd like to see open up for young scientists in the future.

**[0:04:01] Luke Timmerman:** I actually think this conversation pairs quite well with the last episode with Tony Kalesa. Tony is young enough to be David's grandson, but I think they agree on at least one big fundamental issue, that scientific organizations today could do more to unleash the talents of young scientists. Now before we get started with this conversation, a word from the sponsor of The Long Run, AnswerThink. Today's sponsor, AnswerThink, has been consistently recognized by SAP, one of the largest enterprise software companies, as a top business partner for delivering and implementing SAP solutions for small and mid-sized life science companies.

**[0:04:38] Luke Timmerman:** Their SAP certified solutions designed for the life sciences industry are pre-configured, rapidly deployable, and address fundamental business and IT challenges such as integrating your business applications, delivering validated reporting, increasing your speed to market, support for global rollouts, as well as delivering a fully compliant solution that meets FDA's strict standards. Explore how AnswerThink can streamline your business processes to ensure growth. Visit AnswerThink.com slash Timmerman and get a copy of their ebook, Top Three Barriers to Growth for Life Science Organizations.

**[0:05:13] Luke Timmerman:** That's AnswerThink.com slash Timmerman. And I'm pleased to welcome a new sponsor this week, Absci. Absci is all about creating new possibilities in the realm of protein-based therapeutics. What does this mean? Abcci has a fundamentally different approach to drug discovery. It designs and develops next-gen biologics of any modality, from antibodies to T-cell engagers to completely novel protein scaffolds, using a futuristic format it calls bionic proteins. Because Abcci conducts its screens in its scalable production cell line, it collapses several steps of biologics discovery into one integrated efficient process.

**[0:05:56] Luke Timmerman:** Absci also has a unique computational antibody and antigen discovery approach for isolating fully human antibodies from diseased tissues and using these antibodies to identify novel drug targets. Absci does all this with a powerful combination of deep learning AI and synthetic biology technologies. Absci is already helping some of the best partners in biopharma translate their ideas into drugs. Check them out at absci.com and absci.ai. Now, please join me and David Baltimore on The Long Run.

**[0:06:34] Luke Timmerman:** David Baltimore, welcome to The Long Run Podcast. Thank you. So I want to start off by giving you congratulations for this Lasker Award, which you picked up recently. special achievement, lifetime achievement that really recognizes not just your contributions to biology, but also your work as an administrator and as a mentor to so many scientists through your career and a contributor to public policy debates. There's a lot of breadth in here. And so I wonder, when you got that, just curious, did this stand out for you among all the various awards that you've gotten through your career as special in some way?

**[0:07:17] Luke Timmerman:** Well, yes, it did.

**[0:07:21] David Baltimore:** And for a number of reasons. One of them is the breadth of recognition, because I have in my life tried to participate in all the various aspects of being a scientist. And that includes administrative work. It includes mentoring. It includes the doing of science, the publishing of science. And there really are very few awards that take into account all those aspects. of scientific life. And so I was very honored by the Lasker Award. Also, I knew Mary Lasker and admired her devotion to science, although she herself had no scientific training.

**[0:08:29] David Baltimore:** and so I really appreciated the connection. Yeah yeah well there was a great scientifically

**[0:08:38] Luke Timmerman:** minded citizen I guess you could say someone that that championed research and was a very effective advocate in on Capitol Hill. Yes. Okay so I think one of the through lines listeners of this show recognizes that we like to talk about kind of where scientists and scientific entrepreneurs come from. And they come from many different walks of life, many different backgrounds. So where does your story begin, David? Where'd you grow up?

**[0:09:07] David Baltimore:** I grew up in a suburb of New York City on Long Island, Great Neck, Long Island. And I went to public school there through high school and had the remarkable good fortune that my mother was interested in experimental psychology and was studying at the New School of Social Research in New York. and she saw there an ad for a summer program for high school students at the Jackson Laboratory in Bar Harbor, Maine. And she brought it home and said, would I be interested?

**[0:09:56] David Baltimore:** And I said I would, and I applied and was accepted and spent six or eight weeks that summer between my junior and senior years of high school. Now, why do you think she brought this ad to your attention? I think she had seen that I did well in science-related activities, mainly mathematics at that stage, and that I got a real sense of excitement about learning the underpinnings of the world. as a scientist does. And so...

**[0:10:52] Luke Timmerman:** Where do you think that came from? Like that desire to learn, like that curiosity as a kid?

**[0:10:59] David Baltimore:** I have no idea. Clearly, not many kids have it. But when you do have it, it's pretty obvious to people around. And I've always credited my mother with having recognized this in me. And it really was a recognition of my inheritance from her because she was a scientist.

**[0:11:38] Luke Timmerman:** Now, were you bored in school? Were you not really challenged? Was she seeking to give you a little more challenge?

**[0:11:46] David Baltimore:** Yes, absolutely. I was bored completely in the science part of school because I wasn't challenged. and doing the kind of math that we did in high school was a trivial exercise for me.

**[0:12:13] Luke Timmerman:** So you went to Jackson Lab for part of a summer when you were in high school. What was important about that experience?

**[0:12:22] David Baltimore:** What was important was that I, first of all, met real scientists. Many scientists came and spent the summers at Jackson Lab. The program that I was in was for 27 or something high school students. And each of us had three mentors who asked us to do simple experiments in their own interests. And so I was doing experiments, working at the forefront of science, because I was asking questions that didn't have a known answer. And that was just incredibly exciting to discover that the frontiers of knowledge were accessible to me as a high school student without a whole lot of background.

**[0:13:37] David Baltimore:** and I was mentored by three people I later discovered were three of the greatest scientists in biology, people who were at the forefront of developmental biology. Jackson was a laboratory of mouse genetics and they were all geneticists.

**[0:14:05] Luke Timmerman:** And this would have been early to mid 50s prior to Watson Crick's discovery?

**[0:14:11] David Baltimore:** No, it was just after Watson Crick's discovery. That was in 1953. And this was the summer of 1955.

**[0:14:24] Luke Timmerman:** Okay. So were you aware of that at the time, that big discovery? I don't know if that was really publicized at the time very much.

**[0:14:33] David Baltimore:** It was not publicized. I would not have been aware of it. Certainly, my high school's teachers didn't know anything about it or didn't reflect it. But at Jackson, they knew about it. And I don't actually remember whether we discussed it or not.

**[0:14:57] Luke Timmerman:** um okay but you caught the bug there at jackson science like this this world of discovery but it

**[0:15:08] David Baltimore:** was the the bug of experimental science of actually doing experiments and learning about nature and that was the bug that i caught and that that drove me through the rest of my career

**[0:15:24] Luke Timmerman:** Okay. So by the time you graduate and you go off to college, you go to Swarthmore. Why did you pick that place as opposed to some other place?

**[0:15:37] David Baltimore:** Right. So many people thought that I should go to MIT, which was the great Eastern technical school. And I thought about it. In the end, I don't even think I applied because I knew what I wanted to do in life. and therefore I didn't feel I needed the technical education, that that was going to be my life, but that I had a sense there was much more in the world than technical knowledge. And I wanted to expose myself to that, to learn how to interact with the other elements of the world.

**[0:16:32] David Baltimore:** And so I chose to go to a liberal arts school.

**[0:16:36] Luke Timmerman:** And Swarthmore obviously has a great reputation as a small, broad-based liberal arts institution. So you're saying you knew you wanted to be a scientist, but you were actually attracted to the strength in the humanities that they had there.

**[0:16:54] David Baltimore:** That's right.

**[0:16:58] Luke Timmerman:** So how did it work for you? Like, what did you immerse yourself into and what did you learn there as well?

**[0:17:04] David Baltimore:** I was originally a biology major. I actually switched into chemistry in my last year for complicated reasons. I should say that chemistry is the foundation of biology. And so a chemistry major is probably the best thing a biologist, a nascent biologist can do. Um, and, but I had roommates who were in other areas of, of, uh, human knowledge, um, in the arts, in political science. Um, I had friends, uh, who were in a whole variety of, of activities.

**[0:17:59] David Baltimore:** I actually wasn't particularly close friends with other scientists there, although there was a core of us who were aware that biology was undergoing a revolution and who wanted, all of us wanted as much knowledge as we could get about what was going on in contemporary biology. and the Swarthmore educational system for honors students was that we took seminars, two seminars a semester for the last two years. And those seminars were driven by the students. And so we could drive those seminars to give us an understanding of what was going on in biology, even though the faculty itself didn't really understand what was going on.

**[0:19:00] David Baltimore:** because their own education had occurred well before the structure of DNA was elucidated. And the issues about genetic biology and regulatory biology, which were then explosively developing, were to them not personally understandable.

**[0:19:29] Luke Timmerman:** It sounds like you had a lot of freedom and latitude to direct your studies. And you were not just following the lead of the faculty or, you know, repeating what you read in some textbook back on the test.

**[0:19:42] David Baltimore:** That's exactly right. And it was not just me, but as I say, there was a small cadre of us, all of whom went on in biology.

**[0:19:56] Luke Timmerman:** You know, this also reminds me of, you know, my book on Lee Hood, a contemporary of yours. When I looked at his life and talked with him about this period, he had that same kind of freedom and latitude. But there was also a grounding in heart. He went to Caltech as an undergraduate and like the core curriculum of the chemistry, the physics, the math that you just had to work through and really push yourself. But, you know, he also pointed to the same thing you did about the joy of the beauty of learning about humanities.

**[0:20:32] Luke Timmerman:** Like he really enjoyed those elective courses that broadened his perspective.

**[0:20:39] David Baltimore:** Yeah, it's interesting that we had similar experiences in two very different schools.

**[0:20:44] Luke Timmerman:** But was that characteristic of your generation, you think, or maybe just kind of an unusual set of circumstances the two of you had?

**[0:20:56] David Baltimore:** I can't say because going to schools like Caltech and Swarthmore, you're with a very select group of people. And those people were all extremely curious about the world, extremely excited to be introduced to new ideas, unfolding ideas. and so in the world in which I found myself at Swarthmore yes we were an unusual group of people who together were trying to uncover what it was that the world held

**[0:21:53] Luke Timmerman:** but I wonder if looking back now many years later you see any particular advantage that came from that broad-based education? Since so many scientists come up in more narrow confines, I guess you could say, where they're not encouraged or they don't take that humanities, those kind of courses to the same extent.

**[0:22:17] David Baltimore:** That's right. And I give credit to my Swarthmore education for the fact that I could become a university president. Because when you're involved in high-level administration, and particularly when you're president of an organization, the kinds of problems you are faced with are not technical problems. They're problems of personal interaction among people. their problems of judging who is good in what kind of job and who can most effectively contribute to a communal activity like running a university.

**[0:23:16] David Baltimore:** And so it's your sense of people which is paramount. And I think I developed the ability to do that, maybe not as well as others, but at least well enough. Because I went to Swarthmore. Interesting. Because I had spent my time interacting with people from all walks of intellectual life.

**[0:23:47] Luke Timmerman:** And you were also getting to do some research in the lab as an undergraduate, correct?

**[0:23:56] David Baltimore:** Not at Swarthmore so much. But I did. First of all, I spent a summer at Cold Spring Harbor. And in fact, that was critical in my development, having that experience. and I did an undergraduate thesis in chemistry, but I did it at the University of Pennsylvania

**[0:24:25] Luke Timmerman:** working in a chemistry lab. Okay. Okay. Maybe we could, I don't think we have enough time to cover all of the steps in your career. There's been so much, but I am like, when I look at your bio and And if I were to describe your work in a single word, I mean, virologist is maybe the first word. I mean, virology led in lots of different directions. It opened up all kinds of frontiers, but it starts there.

**[0:24:57] Luke Timmerman:** How did you arrive at virology? What was it about viruses that excited you?

**[0:25:04] David Baltimore:** Well, you have to remember that the foundations of molecular biology were laid by virologists. They were mostly people working on bacteriophage, which are viruses that grow in bacteria. And I was aware of that. I was aware that Luria and Delbruck and the people, even Watson, the people who were laying the foundations of the field, did it by studying viruses. and so when I went to graduate school I am gravitated to laboratories of virology I worked actually with with Cy Leventhal who was one of the early molecular biologists himself actually trained in physics um and but i i had the sense that what i really wanted to do was to understand how mammals worked how humans worked how mice worked um

**[0:26:27] David Baltimore:** and it occurred to me that if i wanted to take the lesson of of uh of virology, but apply it to higher systems, to more complex systems of living systems, that I should study animal viruses rather than bacteria. So in my first year of graduate school, I took that question to the faculty. I took it first to Cy Leventhal. And he said it was an interesting perspective, but he didn't know much about it. And then I took it to Salvador Luria.

**[0:27:19] David Baltimore:** And Luria had written the then only textbook on virology and had written about animal viruses. So he had understood that there were viruses that affected animals and that you could study them quantitatively. And so he said to me, I'll tell you, I don't know if they're ready for prime time yet, but why don't you find out? And so he arranged for me to work the following summer with a quantitative animal virologist, Phil Marcus, and to take a course in Cold Spring Harbor in animal virology, which was a new course then being started or then started.

**[0:28:15] David Baltimore:** And I did that. And I realized that you could work quantitatively with animal viruses. It was more clumsy. It took longer to do experiments than with bacteriophage, but you could come out with quite precise answers. And so I said, I want to do my thesis in animal virology. And I chose to work with one of the people who taught the course at Gold Spring Harp named Richard Franklin. Richard was a professor then at the Rockefeller University.

**[0:28:52] David Baltimore:** And so I switched from MIT, where I had been a graduate student, to Rockefeller and did my thesis with him.

**[0:29:01] Luke Timmerman:** Now, at this time, were you thinking about just fundamental understanding of the viruses themselves and how they differ and what kind of effect they might have on the animal or the higher organism? Or were you thinking of the virus as a tool that could perturb the higher organism?

**[0:29:22] David Baltimore:** um i i actually wasn't smart enough to frame that question um i i and it was a sort of a gut feeling that if i worked in animal viruses i was going to find myself able to think about mice. I mean, I had been at Jackson Lab for a summer where mice were the organism of choice. And so that was an experience that stayed with me. And I felt through my career that if I could make a problem work in mice, that I could get the kind of depth of knowledge that related to humans, but at the same time, be able to manipulate the organism on a reasonable timescale.

**[0:30:23] David Baltimore:** and so I chose to go to work on animal viruses with that feeling in mind and it turned out to be true that first of all that the work that we did on animal viruses did teach us new things about how animal cells work and how mouse cells work, and ultimately became very good probes of the immune system, for instance, of animals. But at that time, I wasn't thinking much about the immune system. That interest of mine developed later.

**[0:31:06] Luke Timmerman:** Well, so many things came later from that early decision to go into virology. I mean, learning about the work that made you famous with the reverse transcriptase and how that got you deep into molecular biology, nucleic acids, like how that information is carried through organisms that really challenged the central dogma at the time. And then later, right, then he started working more on the immunology, like the recombinations there. So you mentioned a gut feeling that this was going to be a fruitful area.

**[0:31:53] Luke Timmerman:** But this is really important for a lot of young scientists, like thinking about how do you decide what to work on? And you had no idea at the time that it would lead you down all these different paths. But how did you stay focused?

**[0:32:15] David Baltimore:** Well, I actually didn't stay focused. I, you know, I have analogized my experience in science and the way I feel about, in fact, how all young scientists are educated. I've analogized it to an hourglass. In an hourglass, you put a lot in at the top. It comes down to a very narrow channel, and then it explodes at the bottom. To me, you start out in education learning everything. You take all the courses. You're told to take all the courses.

**[0:33:08] David Baltimore:** And you get a broad sense of the world. But when you go to graduate school, you focus down on a very narrow area. And you have to. And that's how you learn what knowledge is. But then you later can explode out the bottom and take many different paths. and it's the bottom of the hourglass. And so I was able to do that first studying viruses, but then viruses led me to think about cancer. And cancer was the entree to thinking about cells.

**[0:34:00] David Baltimore:** And once I was thinking about cells, I said, well, cells are organized in systems in the body. And the most interesting system to me was the immune system, because that's how we sense the pathogens that attack human life. And so I moved out into the immune system, working on the recombination process that leads to antibodies and T-cells, but ultimately working on innate immunity and issues that were closer to disease. And now I'm actually working very much with the biotech industry, trying to apply the knowledge that we have to human diseases.

**[0:35:00] Luke Timmerman:** Today's sponsor, AnswerThink, has been consistently recognized by SAP, one of the largest enterprise software companies, as a top business partner for delivering and implementing SAP solutions for small and mid-sized life science companies. Their SAP-certified solutions designed for the life science industry are pre-configured, rapidly deployable, and address fundamental business and IT challenges such as integrating your business applications, delivering validated reporting, increasing your speed to market, support for global rollouts, as well as delivering a fully compliant solution that meets FDA's strict standards.

**[0:35:36] Luke Timmerman:** Explore how AnswerThink can streamline your business processes to ensure growth. Visit answerthink.com slash Timmerman and get a copy of their ebook, Top Three Barriers to Growth for Life Science Organizations. That's answerthink.com slash Timmerman. And I'm pleased to welcome a new sponsor this week, Absci. Absci is all about creating new possibilities in the realm of protein-based therapeutics. What does this mean? Absci has a fundamentally different approach to drug discovery. It designs and develops next-gen biologics of any modality, from antibodies to T-cell engagers to completely novel protein scaffolds, including a futuristic format it calls bionic proteins.

**[0:36:18] Luke Timmerman:** Because AVSI conducts its screens in its scalable production cell line, it collapses several steps of biologics discovery into one integrated efficient process. AVSI also has a unique computational antibody and antigen discovery approach for isolating fully human antibodies from diseased tissues and using these antibodies to identify novel drug targets. AVSI does all this with a powerful combination of deep learning AI and synthetic biology technologies. Absci is already helping some of the best partners in biopharma translate their ideas into drugs.

**[0:36:52] Luke Timmerman:** Check them out at absci.com and absci.ai. Things really changed for you in the 70s. You win the Nobel Prize in 1975, and I think it was that same year that the Asilomar Conference was put together. And I know you had something to do with that. Again, coming back to some of your humanities roots and thinking about how science connects to the society at large. Why did you get involved with that question about how recombinant DNA ought to be regulated or ought to develop over time?

**[0:37:36] David Baltimore:** We were faced with the recombinant DNA revolution, which had very remarkable implications for how science was done, but also had some people particularly worried about whether we were going to create problems of one form or another. And so I said, I thought it was a problem that scientists should take on. and that we should come together as scientists to think through what the dangers might be, as well as what the opportunities might be in this new science, this new way of doing biology.

**[0:38:45] David Baltimore:** And the group of us that met and thought about this were of one mind, that we should find a route to responsible behavior. and Paul Berg, Maxine Singer, and others whom I worked with on this were very important in there and very much people who thought broadly about social responsibility.

**[0:39:22] Luke Timmerman:** Now, were there a lot of scientists at the time who thought, oh, why bother with this? The public doesn't understand what we're doing. Just keep focused on our work and advancing the field.

**[0:39:35] David Baltimore:** Yes, that there were many people who felt that. But I think they sensed that it was not possible to ignore. the danger elements. And I think we understood from the very beginning that we were moving towards genetic manipulation of organisms and ultimately developing the ability to do this in humans. And that we had to think about that power because that power was the power to alter the evolution of our own species.

**[0:40:28] Luke Timmerman:** And there's a serious ethical conversation that necessitates bringing more than just scientists to the table. And if you didn't have this kind of multilateral dialogue, whatever you want to call it, I mean, there was a danger that the public fear could end up shutting down the funding, the work. You could really lose a lot as scientists.

**[0:40:58] David Baltimore:** Absolutely. So it was in our own interests to have the Asilomar meeting. It wasn't just in the interests of the larger community. but we Silamar was a meeting of scientists we had some ethicists we had some lawyers who came we had newspaper people but the core of it was science in the more recent considerations of gene editing which we've now had two summits and are in the process of organizing a third, the ethicists are playing a much larger role because we're getting closer and closer to actually being able to manipulate the genes of humans.

**[0:42:06] David Baltimore:** And that is an issue which scientists are no better at thinking about than ethicists are. And we know that.

**[0:42:23] Luke Timmerman:** Yeah, I want to come back to that a little bit later. But you mentioned your work with industry just briefly. When did that begin for you? Biotech, you know, conventionally traced its beginnings to Genentech getting started around this time, 1976. When did you get involved and how?

**[0:42:43] David Baltimore:** I got involved around 1970 because when I discovered the reverse transcriptase, one of the first things that I understood we should study was how the enzyme starts chains of product. because every polymerase is faced with the problem of starting a chain, starting to copy a piece of DNA, starting to copy a piece of RNA. You have to begin at a beginning. It's a catalyst. And there's no chain there to begin on. So there are enzymes that can make it beginning chain.

**[0:43:44] David Baltimore:** But what we discovered very early on was that the reverse transcriptase needed a primer. And that that primer was a piece of DNA that could hybridize to a template at some place, wherever. And that would begin a copying process by the reverse transcriptase. And so having primers was critically important. You couldn't start a chain without them. And we showed that. And it was actually something that I had worked on during my training. So it was something I was thinking a lot about.

**[0:44:37] David Baltimore:** And the primer that was most important was oligo-DT, was a short stretch of T residues, thymine or thymidylate residues. and why was that important? Because messenger RNAs started at their three prime end with a poly A and that was known and so you could copy any messenger RNA using oligo DT as a primer, a short T stretch and we showed that that was true um now where do you get oligo dt well it turns out there was a company that had been formed in the late 1960s by a chemist at at brandeis university it was it was called um collaborative research.

**[0:45:51] David Baltimore:** And collaborative research was housed in a building in Waltham, Massachusetts. This guy, Ori Friedman, had left Brandeis and had formed this company. It was literally the first company in biotechnology. And what it was formed to do was to manufacture nucleic acids, strings of A's, G's, C's, and T's. But the easy ones to do were homopolymers, oligo-DT being one of those. And so they made the primer I wanted.

**[0:46:35] Luke Timmerman:** And this is even before Cohen and Boyer, recombinant DNA, Paul Berg. Yeah. And so, I mean, could you make these primers yourself in the lab? I mean, I suppose, but.

**[0:46:51] David Baltimore:** We knew how to link triphosphates. So, yes, you could make it. But it was significant chemistry to do that and then to purify it and to characterize all of that. And that's what this company was doing. So I wasn't going to try to make this stuff, but I was overjoyed that Ori Friedman was making it.

**[0:47:24] Luke Timmerman:** So here you have a company that's providing a useful service tools to help you do your research, which is asking and answering questions one after the other.

**[0:47:36] David Baltimore:** Right. And so I bought his product from him. But we became good friends and I knew the people in the company. And so when recombinant DNA came along, I said to them, this is the future of your company. And we got together and formed Collaborative Genetics, which was an offshoot of collaborative research. And this is this is 1975.

**[0:48:15] Luke Timmerman:** So would you have been on the Scientific Advisory Board or did you have some other role?

**[0:48:20] David Baltimore:** I was on the Scientific Advisory Board, but I was also a founder. along and I brought some friends of mine along with this David Botstein, Jerry Fink, Ron Davis. And because it really looked like yeast could be the foundation for it. And these guys were the first yeast geneticists.

**[0:48:48] Luke Timmerman:** Now, so you clearly saw an upside to working with a company and helping facilitate this new wave of recombinant DNA research. But, you know, this was not a universal view across the world of academic science. People looked at industry as kind of the dark side or, you know, hacks. Why would you want to get involved with that sort of thing? And your answer to them was?

**[0:49:15] David Baltimore:** this was going to be the route to which the science that we were doing was relevant to human interests. And we couldn't do that in a university. It had to be done in a company. and we wanted to help that company form and focus and to bring the newly developing knowledge because in those days, I mean, it's still true, knowledge was changing literally day by day. Our understanding of how to put pieces of DNA together, how to copy them, how to put DNA into cells, into organisms, how to manipulate.

**[0:50:11] David Baltimore:** The whole splicing revolution told us that there were elements of this problem that were going to be really difficult to deal with. and so a company seemed like the right thing to do. You're right. Many people saw it as the dark side, but I think because I had been so advantaged by Ori Friedman's original decision to form a company, and so he had been ahead of me, And that's exactly where a company should be with the right questions, taking advantage of new knowledge.

**[0:51:03] Luke Timmerman:** And I suppose getting established, winning the Nobel as young as you were, 37, I mean, people in industry knew who you were. The phone would ring. They did. um now how did that inform that early career success like having all the latitude that you did and the ability to um to to move the field forward when you were in your 30s how did that inform the way you went about uh leading institutions which came later like the whitehead and Caltech?

**[0:51:42] David Baltimore:** Having the prominence that I did as a Nobel laureate did open doors and did mean that people would take my call if I called them. That's absolutely true. And it also was a responsibility that I had. and I think that every Nobel laureate feels, to be a spokesman for the community, to be a public face of the science. And so when I was asked by Jack Whitehead, advise him about forming an institute. That was partly because I was prominent enough that his advisor knew me and advised him to ask me.

**[0:52:53] David Baltimore:** We hit it off and he enabled me to form the Whitehead Institute. But you

**[0:53:02] Luke Timmerman:** You used, to use a modern term, your platform. You used your accomplishments, your stature to start this independent institute. You also, one of the things you did that I've read about was creating this fellows program where you gave a lot of young scientists a lot of latitude, kind of like you had had. Right. Why did you do that?

**[0:53:28] David Baltimore:** Well, it was partly because I had had it. I was learning from my own experience that given resources and freedom, a young scientist will, can find his or her own pathway. and that it really was important that young scientists be given that opportunity because they would find a direction that might not be obvious to those of us with lots of experience because the experience that we had tended to channel us into established pathways. and I wanted an opportunity for young people to get into their own pathways, to think about new ways to do science.

**[0:54:35] David Baltimore:** And so I felt that the system that we were developing of graduate school and postdoctoral training that was increasingly long, five, six years, seven years to train a student, and then another five years for a postdoc, meant that the young scientists with fresh ideas were being channeled into their mentors' ideas, their mentors directions, and weren't able until really until they got tenure in their 40s to set out in their own personal direction. This seems like a really important opportunity in my 20s.

**[0:55:35] Luke Timmerman:** Well, yeah, this seems like a really important point in how the scientific enterprise has changed between your generation and let's say mine and younger. And that is at the part of my research for the hood book, I found that the average first time R01 grant winner when he was coming up was something like 30. That's right around when he got his and got on the faculty and got tenure shortly thereafter. And now it's in the early 40s.

**[0:56:03] Luke Timmerman:** So a lot of people just don't make it all the way to that other side. They have to find some other line of work. Do you worry about this?

**[0:56:13] David Baltimore:** I worry about it a lot. And it's deeper even than just the way you put it, because by the time people are in their 40s, They have families. They have much wider responsibilities. They're being pulled away from science by the responsibilities of the world. whereas when they're younger they're less encumbered and more able to put their time and energy into finding the new directions that I think are central to the progress of science. So I think we've gone in exactly the wrong direction.

**[0:57:10] Luke Timmerman:** Is this the biggest job of institutional leadership today is creating that space where young people can spread their wings scientifically?

**[0:57:21] David Baltimore:** Yes, I think that would be wonderful, but I think very few institutional leaders are thinking that way. And the program that I started at Whitehead was meant to show that there is another way to bring along the development of the best young scientists. and it has worked incredibly well. And other people have tried to mimic it. And there are other programs that give young people freedom now. But none of them, I think, have been as successful as the Whitehead program for reasons that I can go into.

**[0:58:16] Luke Timmerman:** Now, so there's this human piece that, let's just say, could use some work or, you know, in terms of on ramps for young people into the sciences. But at the same time, there's I mean, you must look with some measure of amazement. I know I do at the tools that are available to ask and answer questions in biology from sequencing to synthesis to imaging, structural biology, CRISPR. I mean, it's really pretty amazing what the tools that are at the disposal to enable discovery.

**[0:58:53] Luke Timmerman:** How do you see us really taking advantage of these tools to advance human health to the fullest?

**[0:59:06] David Baltimore:** We need to come together in collaborative ways to bring these tools together, because often it's not just one tool by itself. It's imaging and sequencing and genetics and this and that that make for a new direction. And so we do have to come together. But in the end, it's also the imagination of a single individual or sometimes of a couple that makes it happen. And so I think it's as important to be educating the individual as it is to being able to put together the structures of collaboration.

**[1:00:16] David Baltimore:** and I don't think people need to wait until they have all the tools at their disposal because by the time they're good at computation and at imaging and at genetics and at hand, they're going to be too old. So they have to just start young and incomplete. in their toolbox. But what has always struck me is that I go into a laboratory and talk to the people who were there. And they're all so knowledgeable about what they're working with and what they're thinking about.

**[1:01:07] David Baltimore:** And these are kids who have been at it for two years, three years. They're all newbies. And yet here they are, really sophisticated, narrowly sophisticated, but truly sophisticated. It doesn't take a lot. And that's what I discovered at Jackson Lab when I was in high school. It doesn't take a lot to be able to start investigating new questions.

**[1:01:43] Luke Timmerman:** Well, you know, you said starting young, and I was just going to ask, how young? I mean, should this be starting in high school? Like encouraging young people to think about the possibilities in biology and that joy of discovery and satisfying your curiosity. A lot of young people just don't get exposed to it.

**[1:02:05] David Baltimore:** That's right. And the more that can get exposed, the better in high school. My very good friend, Irv Weissman, and I often share reminiscences because he also started working in science in high school in Montana. And we feel very strongly that high school students should have the opportunity to be exposed to experimental science, and often are not.

**[1:02:55] Luke Timmerman:** But now, coming out of the pandemic of COVID-19, there have been a lot of changes to the way science gets done, certainly a lot more awareness of the work and its ability to do amazing things very quickly. What do you think will be, I mean, there has been new collaborative efforts. There's been, science has sped up with the whole open source, you know, publishing of preprints. There's been some more funding in some spots. Do you think the scientific enterprise is going to be in better shape coming out the other side of this?

**[1:03:37] David Baltimore:** What I don't see is the development of the opportunity for individuals to take their own directions. And I still think that that's critically important. Much of what you just described, all of which is leading to a supercharging of research in certain ways, is collaborative. And I think that can go a long way to helping the world take advantage of the new science that we have. But I still don't think that you can substitute individual commitment, individual understanding, individual pathways.

**[1:04:48] Luke Timmerman:** Yeah, yeah. So are you generally supportive of things like NIH's young investigators' outreach efforts and NIHMI is trying to do things like this too?

**[1:05:01] David Baltimore:** The more that we have opportunities for young people to think their own thoughts, the better off we are.

**[1:05:12] Luke Timmerman:** So if you were 16 or 18 or 20 starting out today, looking at the world of biology, what would you want to work on?

**[1:05:24] David Baltimore:** Well, I have answered that question many times. and have always focused in neuroscience because the biggest un-understood areas of biology are in the brain, how the brain works, how the brain processes information, how the brain develops imagery. it's all still very obscure and with tremendous opportunity. So I would focus there. But I also believe that you can start anywhere in biology. I mean, other sciences do, but I tend to think about biology. You can start anywhere and find challenging problems that cry out for solution.

**[1:06:34] David Baltimore:** Regulatory biology. We still don't understand gene transcription. We know how an enzyme copies one strand of DNA into RNA, and RNA can make protein. But we don't understand the control of that process at all well. And in fact, with the recent discoveries of these lipid droplets organizing regulatory machinery, we have a new challenge in front of us that now I see young people gravitating toward. And I'm very excited by it.

**[1:07:24] Luke Timmerman:** it's a it's basic research, learning some of those fundamentals and then seeing where that leads. That could lead you down to new insights into cancer biology, into immunology, lots of different ways. Last thing I want to ask you, David, now that you're in your eighties, you can do a lot, do whatever you want, lots of different things, but how do you keep your mind fresh? focused on things that you want to understand deeply, but also open and curious to new things?

**[1:08:10] David Baltimore:** I have chosen to close my laboratory. And so I'm no longer trying to organize a group to investigate investigate, to directly investigate problems. But I'm still interested in the directions of science. I read about it. I talk to people about it. I go to advisory board meetings of various institutions where I hear about the latest developments. And that keeps me excited. keeps me interested. And I'm aware of, in a sense, the full range of complexity that goes into science, that the new focus in computational work in the fusing of imagery with quantitative thinking.

**[1:09:29] David Baltimore:** And that is all very satisfying to me. But I'm no longer creating any of it myself.

**[1:09:40] Luke Timmerman:** Well, you don't necessarily need to have your own lab to create. I think I read somewhere that you have 20 of your trainees at one point or another end up in the National Academy of Sciences. That's correct. So you have this whole network of people out there who are pursuing their own curiosities and interests and making discoveries that, you know, you kind of help set in motion, but can kind of watch from afar.

**[1:10:08] David Baltimore:** And I'm still trying to help them. I work with them in fostering their own careers. And so I'm still in contact with many of the people who have been so successful coming out of my lab.

**[1:10:28] Luke Timmerman:** Well, I can say it's been a pleasure speaking with you, David. I know that you are at this point where you can have a lot of impact on a young person's life. One little anecdote, I'll tell you, you know, I had a summer intern this summer. And the very first assignment I had her do was to cover one of the startup companies that you've been working on, Appia Bio. And I don't know, I mean, you only spoke with her for maybe 15 minutes.

**[1:10:56] Luke Timmerman:** But I mean, that just I mean, that made her summer. And I don't know what she you know, again, I don't know what she's going to go on and do in the industry, but it definitely provided a spark. It's a real privilege to be able to do that.

**[1:11:10] David Baltimore:** Well, I and I enjoy it immensely.

**[1:11:13] Luke Timmerman:** Well, thank you, David, for your time today on The Long Run.

**[1:11:18] David Baltimore:** Very nice talking with you.

**[1:11:21] Luke Timmerman:** Thanks for listening to The Long Run, a production of Timmerman Report. Pedro Rosado of Headstepper Media was the sound editor. Music is from D.A. Wallach. See you next episode.
